Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of upadacitinib in Chinese adolescents and adults with moderate-to-severe atopic dermatitis
CTR20232233Phase 4Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Aug 2023; status: active.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232233.